Zacks: Analysts Anticipate Stryker Co. (SYK) Will Post Earnings of $1.60 Per Share

Wall Street analysts forecast that Stryker Co. (NYSE:SYK) will announce $1.60 earnings per share for the current quarter, Zacks reports. Ten analysts have issued estimates for Stryker’s earnings. The highest EPS estimate is $1.64 and the lowest is $1.58. Stryker reported earnings of $1.48 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 8.1%. The firm is expected to announce its next quarterly earnings report on Tuesday, April 24th.

On average, analysts expect that Stryker will report full year earnings of $7.12 per share for the current fiscal year, with EPS estimates ranging from $7.08 to $7.17. For the next fiscal year, analysts anticipate that the company will report earnings of $7.82 per share, with EPS estimates ranging from $7.69 to $7.95. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Stryker.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.01. The company had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.78 earnings per share.

A number of equities research analysts have recently weighed in on the company. SunTrust Banks restated a “buy” rating and set a $179.00 target price (up previously from $161.00) on shares of Stryker in a research report on Friday, January 26th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $163.00 price objective on shares of Stryker in a research note on Tuesday, January 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research note on Wednesday, January 31st. Leerink Swann lifted their price objective on Stryker from $177.00 to $184.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Finally, Oppenheimer reaffirmed a “hold” rating and set a $165.00 price objective on shares of Stryker in a research note on Thursday, February 1st. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the stock. Stryker has a consensus rating of “Hold” and an average target price of $162.50.

Stryker (NYSE SYK) traded down $1.55 during mid-day trading on Tuesday, hitting $158.32. The stock had a trading volume of 214,188 shares, compared to its average volume of 1,423,516. The company has a market capitalization of $59,890.00, a P/E ratio of 59.07, a P/E/G ratio of 2.30 and a beta of 0.70. Stryker has a 12 month low of $126.00 and a 12 month high of $170.00. The company has a current ratio of 2.29, a quick ratio of 1.59 and a debt-to-equity ratio of 0.66.

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be paid a $0.47 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.19%. Stryker’s payout ratio is 70.15%.

In other Stryker news, VP William E. Berry, Jr. sold 1,306 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $164.42, for a total value of $214,732.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Graham A. Mclean sold 2,984 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $160.53, for a total value of $479,021.52. Following the completion of the transaction, the insider now directly owns 9,100 shares of the company’s stock, valued at $1,460,823. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,840 shares of company stock valued at $2,749,989. Insiders own 7.40% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Truewealth LLC bought a new stake in shares of Stryker in the fourth quarter valued at about $110,000. Sawyer & Company Inc bought a new stake in shares of Stryker in the fourth quarter valued at about $125,000. Sit Investment Associates Inc. lifted its holdings in shares of Stryker by 114.3% in the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 440 shares in the last quarter. Virtue Capital Management LLC bought a new stake in shares of Stryker in the fourth quarter valued at about $133,000. Finally, San Francisco Sentry Investment Group CA lifted its holdings in shares of Stryker by 47.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares in the last quarter. Institutional investors own 74.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://ledgergazette.com/2018/02/20/zacks-analysts-anticipate-stryker-co-syk-will-post-earnings-of-1-60-per-share.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply